Exelixis
EXEL
#1622
Rank
โ‚ฌ8.69 B
Marketcap
31,07ย โ‚ฌ
Share price
2.47%
Change (1 day)
47.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚ฌ0.63 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚ฌ2.16 Billion. , an increase over its 2023 earnings that were of โ‚ฌ0.22 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 โ‚ฌ0.59 B164.69%
2023 โ‚ฌ0.22 B9.89%
2022 โ‚ฌ0.20 B-20.33%
2021 โ‚ฌ0.25 B124.82%
2020 โ‚ฌ0.11 B-67.14%
2019 โ‚ฌ0.35 B-11.94%
2018 โ‚ฌ0.39 B185.09%
2017 โ‚ฌ0.13 B-325.82%
2016 -โ‚ฌ61.8 Million-58.12%
2015 -โ‚ฌ0.15 Billion-37.61%
2014 -โ‚ฌ0.24 Billion9.75%
2013 -โ‚ฌ0.22 Billion65.96%
2012 -โ‚ฌ0.13 Billion-291.63%
2011 โ‚ฌ67.75 M-195.59%
2010 -โ‚ฌ70.88 Million-42.17%
2009 -โ‚ฌ0.13 Billion-18.98%
2008 -โ‚ฌ0.16 Billion-6.99%
2007 -โ‚ฌ0.17 Billion46.3%
2006 -โ‚ฌ0.12 Billion33.25%
2005 -โ‚ฌ83.44 Million-30.92%
2004 -โ‚ฌ0.13 Billion44.29%
2003 -โ‚ฌ83.71 Million12.86%
2002 -โ‚ฌ74.17 Million22.79%
2001 -โ‚ฌ60.41 Million60.14%
2000 -โ‚ฌ37.72 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚ฌ3.86 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ6.98 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ18.66 B 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ7.38 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.05 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ15.34 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.77 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ37.65 Million-106.28%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ25.56 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA